Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Qiagen ( (QGEN) ).
On January 11, 2025, Qiagen N.V. was informed by the Netherlands Authority for the Financial Markets (AFM) of a notification regarding voting rights and share distribution related to BlackRock, Inc. The notification detailed BlackRock’s indirect holdings in Qiagen’s ordinary shares and contracts for difference, reflecting a capital interest of 8.96% and voting rights of 10.01%. This announcement highlights BlackRock’s significant stake in Qiagen, which could influence shareholder decisions and impact the company’s strategic direction.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in the development and provision of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its wide range of products that facilitate the handling of genomic information, with a market focus on enabling customers to gain valuable insights from molecular information.
YTD Price Performance: 2.36%
Average Trading Volume: 860,116
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $10.11B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.